Registre Des Cancers de la Région du Grand Casablanca, RAPPORT D’INCIDENCE 2018–2021 5 éme Edition 2024

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). The breast. 2024;76: 103756.

Article  PubMed  PubMed Central  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(5):331–57.

Article  CAS  PubMed  Google Scholar 

O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev ClinOncol. 2016;13(7):417–30.

Article  Google Scholar 

Sibaud V, Sollena P. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: an updated review for clinical practice. Ann de Dermatol et de Vénéréol. 2023;150(3):208–12.

Article  CAS  Google Scholar 

Diotallevi F, Gioacchini H, De Simoni E, Marani A, Candelora M, Paolinelli M, et al. Vitiligo, from pathogenesis to therapeutic advances: state of the art. Int J Mol Sci. 2023;24(5):4910.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. New England J Med. 2022;386(10):942–50.

Article  CAS  Google Scholar 

Zhou M, Lin F, Xu W, Jin R, Xu A. Decreased SUMOylation of the retinoblastoma protein in keratinocytes during the pathogenesis of vitiligo. Mol Med Rep. 2018;18:3469–75.

CAS  PubMed  Google Scholar 

Sollena P, Nikolaou V, Soupos N, Kotteas E, Voudouri D, Stratigos AJ, et al. Vitiligo-like lesions in patients with advanced breast cancer treated with cyclinedependent kinases 4 and 6 inhibitors. Breast Cancer Res Treat. 2021;185:247–53.

Article  CAS  PubMed  Google Scholar 

Zhang S, Xu Q, Sun W, Zhou J, Zhou J, et al. Immunomodulatory effects of CDK4/6 inhibitors. Biochim et Biophys Acta (BBA) Rev Cancer. 2023;1878(4):188912.

Article  CAS  Google Scholar 

Romagnuolo M, Alberti VS, Riva D, Barberi F, Moltrasio C. Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor palbociclib. Int J Dermatol. 2023;62:6356.

Article  Google Scholar 

Gao S, Wei G, Hao Y. Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review. Pathol Oncol Res. 2023;29:1115.

Article  Google Scholar 

Sharaf B, AlMasri R, Abdel-Razeq N, Salama O, Hama I, Abunasser M, et al. Vitiligo-like lesions in a patient with metastatic breast cancer treated with cyclin-dependent kinase (CDK) 4/6 inhibitor: a case report and literature review. Clin Cosmet Investigat Dermatol. 2022;2022:5–10.

Article  Google Scholar 

Bang AS, Fay CJ, Le Boeuf NR, Etaee F, Leventhal JS, Sibaud V, et al. Multi- center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors. Breast Cancer Res Treat. 2024;204(3):643–7.

Article  CAS  PubMed  Google Scholar 

Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51.

Article  PubMed  Google Scholar